GSD:CA:TSV-Devonian Health Group Inc (CAD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.14

Change

0.00 (0.00)%

Market Cap

USD 0.02B

Volume

0.02M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-14 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NGEN:CA NervGen Pharma Corp

+0.02 (+0.88%)

USD 0.16B
ARCH:CA Arch Biopartners Inc

-0.07 (-4.07%)

USD 0.11B
MIR:CA MedMira Inc

N/A

USD 0.06B
COV:CA Covalon Technologies Ltd.

N/A

USD 0.05B
NRX:CA NurExone Biologic Inc.

-0.01 (-1.59%)

USD 0.03B
TTI:CA Thiogenesis Therapeutics Corp.

-0.02 (-2.74%)

USD 0.03B
KNE:CA Kane Biotech Inc

N/A

USD 0.02B
ZENI-P:CA Zenith Capital Corporation

N/A

USD 0.02B
SBM:CA Sirona Biochem Corp

-0.01 (-9.09%)

USD 0.01B
XRTX:CA XORTX Therapeutics Inc

+0.14 (+5.05%)

USD 8.36M

ETFs Containing GSD:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.45% 61% D- 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.45% 61% D- 55% F
Trailing 12 Months  
Capital Gain -33.33% 37% F 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -33.33% 37% F 43% F
Trailing 5 Years  
Capital Gain -54.84% 69% C- 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -54.84% 69% C- 39% F
Average Annual (5 Year Horizon)  
Capital Gain 28.50% 86% B+ 76% C+
Dividend Return 28.50% 86% B+ 76% C+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 99.54% 14% F 27% F
Risk Adjusted Return 28.63% 81% B- 74% C
Market Capitalization 0.02B 71% C- 71% C-

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.